Status:

TERMINATED

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Schizophrenia

Eligibility:

All Genders

18-51 years

Phase:

PHASE3

Brief Summary

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schiz...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Signed and dated written informed consent.
  • Clinically stable outpatients who have been diagnosed with schizophrenia (as per Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5)).
  • Patients, who completed participation in the parent trial.
  • Women of childbearing potential must use highly effective methods of birth control.
  • Have a study partner who interacts with the patient on a regular basis. Further inclusion criteria apply.
  • Exclusion criteria:
  • Participant who developed DSM-5 diagnosis other than Schizophrenia or any condition that would prevent the patient from participating in the extension trial since enrolment into the parent phase III trial.
  • Any suicidal behavior and/or suicidal ideation of type 5 based on the Columbia Suicidality Severity Rating Scale (C-SSRS) in parent trial and up to and including Visit 1 of this study.
  • Positive urine drug screen ≥ 3 times during the treatment period of parent trial.
  • Patients who are currently or wish to participate in another investigational drug trial.
  • Any clinically significant finding or condition in the judgment of the investigator that would jeopardize the patient´s safety while participating in the trial or their capability to participate in the trial.
  • Further exclusion criteria apply.

Exclusion

    Key Trial Info

    Start Date :

    March 21 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    March 18 2025

    Estimated Enrollment :

    1362 Patients enrolled

    Trial Details

    Trial ID

    NCT05211947

    Start Date

    March 21 2022

    End Date

    March 18 2025

    Last Update

    May 28 2025

    Active Locations (303)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 76 (303 locations)

    1

    Advanced Research Center, Inc.

    Anaheim, California, United States, 92805

    2

    Clinical Innovations, Inc

    Bellflower, California, United States, 90706

    3

    ProScience Research Group

    Culver City, California, United States, 90230

    4

    Collaborative Neuroscience Network, LLC (CNS)

    Garden Grove, California, United States, 92845